menu
    • menu
    [{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Entinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Entinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Entinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Entinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of North Carolina \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Entinostat

    Menu

    Entinostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of North Carolina

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            University of North Carolina

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entinostat,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Experimental Drug that Boosts Immunotherapy Shows Promise in Bladder Cancer Study

                            Details : When treated with entinostat in combination with immunotherapy, two-thirds of mice had a complete disappearance of their tumors and none of the mice had relapse of their tumors when taken off the treatment.

                            Brand Name : MS-275

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 16, 2021

                            Lead Product(s) : Entinostat,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Syndax Pharmaceuticals

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Syndax Pharmaceuticals

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entinostat,Exemestane,Goserelin Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat + Exemestane in H...

                            Details : The trial did not achieve the primary endpoint of demonstrating a statistically significant overall survival (OS) benefit over hormone therapy alone.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 21, 2020

                            Lead Product(s) : Entinostat,Exemestane,Goserelin Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Syndax Pharmaceuticals

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Syndax Pharmaceuticals

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entinostat,Exemestane

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Citigroup

                            Deal Size : $115.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purch...

                            Details : The Company's lead product candidate, entinostat, a class I HDAC inhibitor, is being tested in a Phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer and has been evaluated in combination with several approved PD-1...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 12, 2020

                            Lead Product(s) : Entinostat,Exemestane

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Citigroup

                            Deal Size : $115.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Syndax Pharmaceuticals

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Syndax Pharmaceuticals

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entinostat,Exemestane

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook

                            Details : Syndax Pharmaceuticals is on track to file for regulatory approval in 2020 and to become a fully-integrated oncology company with the launch of entinostat in HR+ breast cancer expected in 2021.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 10, 2020

                            Lead Product(s) : Entinostat,Exemestane

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth